ADP-lnduced Platelet Activation
- 1 January 1997
- journal article
- research article
- Published by Taylor & Francis in Critical Reviews in Biochemistry and Molecular Biology
- Vol. 32 (6) , 437-502
- https://doi.org/10.3109/10409239709082000
Abstract
Platelet activation is central to the pathogenesis of hemostasis and arterial thrombosis. Platelet aggregation plays a major role in acute coronary artery diseases, myocardial infarction, unstable angina, and stroke. ADP is the first known and an important agonist for platelet aggregation. ADP not only causes primary aggregation of platelets but is also responsible for the secondary aggregation induced by ADP and other agonists. ADP also induces platelet shape change, secretion from storage granules, influx and intracellular mobilization of Ca2+, and inhibition of stimulated adenylyl cyclase activity. The ADP-receptor protein mediating ADP-induced platelet responses has neither been purified nor cloned. Therefore, signal transduction mechanisms underlying ADP-induced platelet responses either remain uncertain or less well understood. Recent contributions from chemists, biochemists, cell biologists, pharmacologists, molecular biologists, and clinical investigators have added considerably to and enhanced our knowledge of ADP-induced platelet responses. Although considerable efforts have been directed toward identifying and cloning the ADP-receptor, these have not been completely successful or without controversy. Considerable progress has been made toward understanding the mechanisms of ADP-induced platelet responses but disagreements persist. New drugs that do not mimic ADP have been found to inhibit fairly selectively ADP-induced platelet activation ex vivo. Drugs that mimic ADP and selectively act at the platelet ADP-receptor have been designed, synthesized, and evaluated for their therapeutic efficacy to block selectively ADP-induced platelet responses. This review examines in detail the developments that have taken place to identify the ADP-receptor protein and to better understand mechanisms underlying ADP-induced platelet responses to develop strategies for designing innovative drugs that block ADP-induced platelet responses by acting selectively at the ADP-receptor and/or by selectively interfering with components of ADP-induced platelet activation mechanisms.Keywords
This publication has 297 references indexed in Scilit:
- Cloning and Tissue Distribution of the Human P2Y1ReceptorBiochemical and Biophysical Research Communications, 1996
- Identification of 6H1 as a P2YPurinoceptor: P2Y5Biochemical and Biophysical Research Communications, 1996
- Cloning and Chromosomal Localization of the Human P2Y1 PurinoceptorBiochemical and Biophysical Research Communications, 1996
- Inhibition of fibrinogen binding to human platelets by blockage of Na+H+ exchangeBiochemical and Biophysical Research Communications, 1989
- Spatial distribution and temporal change of cytoplasmic free calcium in human plateletsBiochemical and Biophysical Research Communications, 1988
- Activation of human platelets by ADP causes a rapid rise in cytosolic free calcium without hydrolysis of phosphatidylinositol-4,5-bisphosphateBiochemical and Biophysical Research Communications, 1985
- The presence of diadenosine 5′,5‴-P 1 ,P 3 -triphosphate (Ap 3 A) in human plateletsBiochemical and Biophysical Research Communications, 1983
- Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid-dependent protein kinase systemBiochemical and Biophysical Research Communications, 1979
- Isolation of homogeneous phospholipase A2 from human plateletsBiochemical and Biophysical Research Communications, 1979
- The binding of adenosine-3′,5′-monophosphate by messenger ribonucleoprotein-like particlesBiochemical and Biophysical Research Communications, 1975